Transform [ a drug policy foundation see http://transform-drugs.blogspot.com/
] welcomes the recent shift in approach to the drugs issue, away from heavy handed enforcement towards public health and harm reduction as the guiding principles, and the development of effective regulatory models for some of the less harmful drugs currently in a legal grey area is inevitably going to be an important part of this process. Piperazines, a fairly marginal issue from Transform's perspective, could offer a useful opportunity to experiment with regulation whilst the stakes remain low, rather than leaving the market to self regulate, or opting for another expensive and counterproductive crackdown.
It is such a good idea maybe New Zealand should actually try it!
- Initiate an official consultation as part of a formal engagement between the relevant Government agencies (including the Home Office, the Department of Health and the Treasury and key stakeholders including drug services, police and enforcement, NGOs, user groups, producers and retailers) to consider the three key choices for going forward regarding policy and legislation on recreational piperazines (status quo, regulation, prohibition). The possibility for a 'Class D' or 'restricted list' for lower risk drugs along the lines of the New Zealand model should specifically be included in the consultation.
- That the ACMD produce a report that considers the information available on piperazines, clarifies the legal status and knowledge on of the various substances in question, and makes recommendations on ways forward, in line with similar recent reports on cannabis, khat, methamphetamines etc.
- The ACMD should be specifically required to consider the models brought into New Zealand law, and make direct contact with colleagues on the New Zealand EACD, to discuss their findings and recommendations. (certainly, but avoid justice, corrections, border control, national drug intel, police and the treatment grifters et al/Blair )
- In the short to medium Transform recommends the establishing in of a new 'Class D' within the MDA to enable the licensed sale of certain drugs under the direction of the ACMD.
Labels: ACMD, Advisory Council on the Misuse of Drugs, Harm reduction